Agreements reached under this partnership
Business alliance- 1
To provide emixustat hydrochloride under a compassionate-use program for designated patients in France
- 2
Supply and licensing of emixustat hydrochloride
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
This indicates whether the companies will do more than work together, such as holding each other’s shares or seconding personnel (capital and business alliance).
The accounting treatment of this matter, including the items described above, is currently under discussion with the audit firm, and its impact on the Company's results is currently being examined.
| Item | Details |
|---|---|
| Name of alliance partner | Laboratoires KÔL |
| Alliance partner's location | Clermont-Ferrand, France |
| Type of alliance | Business alliance |
| Details of the alliance | To provide emixustat hydrochloride under a compassionate-use program for designated patients in France, Supply and licensing of emixustat hydrochloride |
| Acquisition price | Contractually undisclosed |
| Contract Date | 2 March 2026 |
| Impact on Business Performance | The accounting treatment of this matter, including the items described above, is currently under discussion with the audit firm, and its impact on the Company's results is currently being examined. |
Items this document does not state (16)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The provision of the necessary manufacturing-related documentation to KÔL has been completed in preparation for starting the manufacture of the active pharmaceutical ingredient in compliance with clinical GMP and preparing an application to the French regulatory authorities for compassionate-use approval.